Top 5 Stocks to Buy Now
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free OSUR Stock Alerts

OraSure Technologies (OSUR) Competitors

OraSure Technologies logo
$4.34 +0.10 (+2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.11 -0.23 (-5.41%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

OSUR vs. QDEL, CERS, UTMD, ANIK, and WST

Should you buy OraSure Technologies stock or one of its competitors? MarketBeat compares OraSure Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OraSure Technologies include QuidelOrtho (QDEL), Cerus (CERS), Utah Medical Products (UTMD), Anika Therapeutics (ANIK), and West Pharmaceutical Services (WST). These companies are all part of the "health care supplies" industry.

How does OraSure Technologies compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, QuidelOrtho had 3 more articles in the media than OraSure Technologies. MarketBeat recorded 3 mentions for QuidelOrtho and 0 mentions for OraSure Technologies. QuidelOrtho's average media sentiment score of 0.70 beat OraSure Technologies' score of 0.00 indicating that QuidelOrtho is being referred to more favorably in the media.

Company Overall Sentiment
QuidelOrtho Positive
OraSure Technologies Neutral

QuidelOrtho has a net margin of -45.57% compared to OraSure Technologies' net margin of -66.42%. QuidelOrtho's return on equity of 4.25% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
QuidelOrtho-45.57% 4.25% 1.56%
OraSure Technologies -66.42%-18.57%-15.71%

QuidelOrtho has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

QuidelOrtho currently has a consensus price target of $14.88, indicating a potential upside of 21.83%. OraSure Technologies has a consensus price target of $3.00, indicating a potential downside of 30.88%. Given QuidelOrtho's stronger consensus rating and higher probable upside, analysts plainly believe QuidelOrtho is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QuidelOrtho
2 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

OraSure Technologies has lower revenue, but higher earnings than QuidelOrtho. OraSure Technologies is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QuidelOrtho$2.73B0.30-$1.13B-$17.82N/A
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A

Summary

QuidelOrtho beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

How does OraSure Technologies compare to Cerus?

OraSure Technologies (NASDAQ:OSUR) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 5.6% of Cerus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
Cerus -4.41%-15.18%-4.38%

OraSure Technologies presently has a consensus price target of $3.00, suggesting a potential downside of 30.88%. Cerus has a consensus price target of $4.00, suggesting a potential upside of 51.52%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Cerus
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A
Cerus$206.13M2.57-$15.63M-$0.05N/A

OraSure Technologies has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Cerus has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 1 mentions for Cerus and 0 mentions for OraSure Technologies. Cerus' average media sentiment score of 0.08 beat OraSure Technologies' score of 0.00 indicating that Cerus is being referred to more favorably in the news media.

Company Overall Sentiment
OraSure Technologies Neutral
Cerus Neutral

Summary

Cerus beats OraSure Technologies on 13 of the 16 factors compared between the two stocks.

How does OraSure Technologies compare to Utah Medical Products?

OraSure Technologies (NASDAQ:OSUR) and Utah Medical Products (NASDAQ:UTMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Utah Medical Products has a net margin of 28.90% compared to OraSure Technologies' net margin of -66.42%. Utah Medical Products' return on equity of 9.13% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
Utah Medical Products 28.90%9.13%8.86%

OraSure Technologies currently has a consensus target price of $3.00, suggesting a potential downside of 30.88%. Given OraSure Technologies' higher probable upside, equities research analysts clearly believe OraSure Technologies is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Utah Medical Products has lower revenue, but higher earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A
Utah Medical Products$38.52M5.49$11.29M$3.3819.67

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OraSure Technologies has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Utah Medical Products has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

In the previous week, Utah Medical Products had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 1 mentions for Utah Medical Products and 0 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.00 equaled Utah Medical Products'average media sentiment score.

Company Overall Sentiment
OraSure Technologies Neutral
Utah Medical Products Neutral

Summary

Utah Medical Products beats OraSure Technologies on 10 of the 14 factors compared between the two stocks.

How does OraSure Technologies compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Anika Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 15.41%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 30.88%. Given Anika Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Anika Therapeutics is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Anika Therapeutics had 2 more articles in the media than OraSure Technologies. MarketBeat recorded 2 mentions for Anika Therapeutics and 0 mentions for OraSure Technologies. Anika Therapeutics' average media sentiment score of 0.40 beat OraSure Technologies' score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Anika Therapeutics Neutral
OraSure Technologies Neutral

Anika Therapeutics has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Anika Therapeutics has a net margin of -9.52% compared to OraSure Technologies' net margin of -66.42%. Anika Therapeutics' return on equity of -5.90% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Anika Therapeutics-9.52% -5.90% -4.52%
OraSure Technologies -66.42%-18.57%-15.71%

Anika Therapeutics has higher earnings, but lower revenue than OraSure Technologies. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$112.82M1.74-$10.88M-$0.79N/A
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A

Summary

Anika Therapeutics beats OraSure Technologies on 11 of the 16 factors compared between the two stocks.

How does OraSure Technologies compare to West Pharmaceutical Services?

OraSure Technologies (NASDAQ:OSUR) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 30.88%. West Pharmaceutical Services has a consensus target price of $340.09, indicating a potential downside of 0.42%. Given West Pharmaceutical Services' stronger consensus rating and higher possible upside, analysts clearly believe West Pharmaceutical Services is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, West Pharmaceutical Services had 7 more articles in the media than OraSure Technologies. MarketBeat recorded 7 mentions for West Pharmaceutical Services and 0 mentions for OraSure Technologies. West Pharmaceutical Services' average media sentiment score of 0.94 beat OraSure Technologies' score of 0.00 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Overall Sentiment
OraSure Technologies Neutral
West Pharmaceutical Services Positive

OraSure Technologies has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

West Pharmaceutical Services has a net margin of 16.85% compared to OraSure Technologies' net margin of -66.42%. West Pharmaceutical Services' return on equity of 19.03% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
West Pharmaceutical Services 16.85%19.03%14.06%

West Pharmaceutical Services has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.60-$68.73M-$1.04N/A
West Pharmaceutical Services$3.07B7.85$493.70M$7.4845.66

Summary

West Pharmaceutical Services beats OraSure Technologies on 16 of the 17 factors compared between the two stocks.

Get OraSure Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OSUR vs. The Competition

Export
MetricOraSure TechnologiesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$291.92M$8.35B$6.74B$12.32B
Dividend YieldN/A2.57%2.68%5.88%
P/E Ratio-4.1715.2125.3923.96
Price / Sales2.607.01530.17107.90
Price / CashN/A16.9345.2953.76
Price / Book0.913.2910.766.41
Net Income-$68.73M$226.25M$3.56B$337.14M
7 Day Performance-2.91%-0.96%1.37%-0.48%
1 Month Performance20.22%-2.77%0.81%0.49%
1 Year Performance44.67%0.16%30.53%28.16%

OraSure Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OSUR
OraSure Technologies
1.3957 of 5 stars		$4.34
+2.4%		$3.00
-30.9%		+39.9%$291.92M$115.02MN/A840
QDEL
QuidelOrtho
3.1185 of 5 stars		$14.57
+3.1%		$14.88
+2.1%		-56.8%$963.54M$2.73BN/A6,500
CERS
Cerus
3.0308 of 5 stars		$2.52
-1.6%		$4.00
+58.7%		+93.3%$512.95M$206.13MN/A290
UTMD
Utah Medical Products
1.5082 of 5 stars		$69.87
+3.0%		N/A+18.8%$216M$38.52M20.67180
ANIK
Anika Therapeutics
2.4819 of 5 stars		$14.61
-0.7%		$17.00
+16.4%		+33.6%$195.86M$112.82MN/A300

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OSUR) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
Elon’s message for America
Elon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...
Stansberry Research | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Elon Is Quietly Doubling Down on This Bizarre Asset
Yahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...
Brownstone Research | Sponsoredtc pixel
“The unseen winner of the AI race” is not SpaceX
Marc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...
Chaikin Analytics | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel